A quantitative assay for ALZ-50 immunoreactivity was evaluated in samples of superior temporal gyrus taken at autopsy from 13 Alzheimer patients and 11 controls. The assayable immunoreactivity appears to be stable for at least 24 hours postmortem but was lost with formalin fixation. The mean value of the Alzheimer patients was tenfold higher than that of the controls (P < .002). The values of four Alzheimer samples overlapped with the low levels seen in controls, but no controls had elevated levels. In this sample population, therefore, the assay had a sensitivity of 69% and specificity of 100%. (J Geriatr Psychiatry Neurol 1991;4:231-235).
Get full access to this article
View all access options for this article.
References
1.
Mirra SS, McKeel DW, Crain BJ, et al: Quality assurance in the neuropathological assessment of Alzheimer's disease: A multicenter study of the consortium to establish a registry for Alzheimer's disease (CERAD). J Neuropathol Exp Neurol1990;49:336.
2.
Wolozin BL, Pruchnicki A., Dickson DW, Davies P.: A neuronal antigen in the brains of Alzheimer's patients. Science1986;232:648-650.
3.
Nukina N., Kosik KS, Selkoe DJ: The monoclonal antibody Alz-50 recognizes tau proteins in Alzheimer's disease brain. Neurosci Lett1988;87:240-246.
4.
Wolozin B., Davies P.: Alzheimer-related neuronal protein A68: Specificity and distribution . Ann Neurol1987;22:521-526.
5.
Hyman BT, Van Hoesen GW, Wolozin BL, et al: Alz-50 antibody recognizes Alzheimer-related neuronal changes . Ann Neurol1988;23:371-379.
6.
Tabaton M., Whitehouse PJ, Perry G., et al: Alz-50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy. Ann Neurol1988;24:407-413.
7.
Love S., Saitoh T., Quijada S., et al: Alz-50, ubiquitin and tau immunoreactivity of neurofibrillary tangles, Pick bodies, and Lewy bodies. J Neuropathol Exp Neurol1988;47:393-405.
8.
Mirra SS, Brown Lee LM, Sumi SM, et al: CERAD neuropathology protocol: Preliminary report on 65 cases clinically diagnosed as Alzheimer's disease. Neurology1989;39(Suppl 1):192.
9.
Hyman BT, Maskey K., Van Hoesen GW, et al: Pathological changes in the multimodal association areas of the superior temporal sulcus in Alzheimer's disease. Neurology1987;37(Suppl 1):168.
10.
Miller BE, Whetsell WO, Haigler H., Ghanbari HADistribution of Alzheimer disease associated proteins in 10 human brains. Ann Neurol; in press.
11.
Hyman BT, Maskey KP, Van Hoesen GW, Damasio AR: The auditory system in Alzheimer's disease (AD): Hierarchical pattern of pathology . Neurology1988;38(Suppl 1):133.
12.
Ghanbari HA , Kozuk T., Miller BE, Riesiing S.: A sandwich enzyme immunoassay for detecting and measuring Alzheimer-disease associated proteins (ADAP) in human brain tissue. J Clin Lab Anal1990;4:189-192.
13.
Ghanbari HA , Miller BE, Haigler HJ, et al: Biochemical assay of Alzheimer's disease-associated protein(s) in human brain tissue. JAMA1990 ;263:2907-2910.
14.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem1951;193:265-275.
15.
Miller BE, Whetsell WO, Haigler H., Ghanbari H.: Distribution of Alzheimer's disease related protein in various regions of human brain (abstract). Soc Neurosci1990 ;20:283.
16.
Joachim C., Morris J., Platt D., et al: Near-absence of altered neuropil neurites in cases of "plaque-only" Alzheimer's disease. Neurobiol Aging1990;11:282-283.
17.
Arriagada PV , Hyman BT: Predominance of A-4 over Alz-50 positive plaques in non-demented elderly. Neurobiol Aging1990;11:324-325.
